Endocrine

Melanotan II

MT-II

Melanotan II is a cyclic alpha-MSH analogue. The Roman numeral identifies a different compound from Melanotan I and should remain attached to the name.

Reviewed September 2026

Residues
7. verified: 7 amino-acid residues; acetylation, amidation and side-chain cyclization do not add chain residues.
Average mass
1,024.2 Da. verified: Reference form: Melanotan II reference N-acetylated, C-terminally amidated cyclic heptapeptide with norleucine, D-Phe and Asp–Lys lactam linkage.; formula C50H69N15O9. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement.
pI
Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.

Reference details

Reference details
Residues7
Average mass1,024.2 Da
pINot established
Identity
AliasesMT-II
Research areaEndocrine

Property basis and sources

These describe the reference compound or formulation, not identification or testing of the supplied lot.

Melanotan II reference N-acetylated, C-terminally amidated cyclic heptapeptide with norleucine, D-Phe and Asp–Lys lactam linkage. Reference only, not a sold-lot measurement.

  • Residues: 7 (verified). 7 amino-acid residues; acetylation, amidation and side-chain cyclization do not add chain residues. Residues source 1
  • Average mass: 1,024.2 Da (verified). Reference form: Melanotan II reference N-acetylated, C-terminally amidated cyclic heptapeptide with norleucine, D-Phe and Asp–Lys lactam linkage.; formula C50H69N15O9. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement. Average mass source 1
  • pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1

Reference scope and linked records

Reference type: Cyclic modified peptide.

This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.

Catalogue context: Melanotan II. The product retains its own name and specification; this link does not certify equivalence to published study material.

Related references

Sources and their scope

  1. Melanotan-II: pilot phase I clinical study. Source for the chemistry or study context discussed above; not an Aminos lot certificate.

Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.

About Melanotan II

Identity and context

The pilot study describes a lactam-bridged heptapeptide containing norleucine, D-phenylalanine, an N-terminal acetyl group and a terminal amide. These structural features cannot be represented faithfully by an ordinary linear sequence using only standard L-amino acids.

Reference classification

Cyclic modified peptide. The linked catalogue product is Melanotan II. This reference does not independently authenticate the material supplied.

Storage and handling

Analytical specification

Check the ring linkage, D-residue and terminal groups. A vial label with only a similar melanocortin name cannot establish which of these structurally related molecules is present.

Storage and experimental handling

Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.

Research evidence

Research evidence for this compound
AreaSummaryEvidence
What the source examinesThe primary phase I pilot involved only three male volunteers. It reported pigmentation alongside effects including nausea, fatigue or somnolence and spontaneous erections. Its small size and early exploratory design limit what can be inferred about safety and efficacy.Source context
What cannot be inferredThe existence of a pilot study is not evidence of a safe tanning product. Findings for Melanotan II must not be substituted with clinical evidence for afamelanotide or bremelanotide, which are different identities and preparations.Evidence limits

References

Sources used for the data on this page, checked September 2026.

  1. Melanotan-II: pilot phase I clinical studyPrimary source for the reference discussion; not lot-specific product evidence.

Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.